Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study

Outcomes improved in patients across all categories of PD-L1 tumor proportion scores in the pembrolizumab/chemotherapy group.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2DFQMpZ